As the use of artificial intelligence (AI) expands among companies, more organizations are establishing training systems to enhance their employees' AI skills. Hanmi Group has announced the launch of a company-wide program aimed at improving employees' AI capabilities and promoting a culture of digital-based business innovation.
On August 6, Hanmi Group revealed that it will implement the 'Hanmi AI Boost Program' for employees across all its subsidiaries, including Hanmi Science and Hanmi Pharmaceutical. The program is designed to support the creation of tangible results through the use of AI and digital technologies.
This initiative goes beyond simple AI application; it is a bottom-up program focused on voluntary execution that aims to improve actual work processes, apply ideas from the field, and disseminate results within the organization. The goal is to establish a performance-oriented culture of AI utilization by systematically supporting the entire process of discovering, implementing, and sharing ideas. This approach is intended to create a virtuous cycle where practical experiences in the field lead to AI innovation throughout the organization.
Notably, cases that demonstrate visible results in improving work efficiency, automation, productivity enhancement, and cost reduction will be recognized and rewarded through monthly excellence awards, monthly communication awards, and an annual innovation award.
A representative from Hanmi Science stated, "The AI Boost Program is an execution-focused initiative that goes beyond technology adoption to create results in real work environments and accumulate these as organizational assets. We will continue to actively support employees' voluntary participation and creative attempts, spreading innovative cases to strengthen Hanmi Group's unique AI-based business innovation culture."
Meanwhile, Hanmi Pharmaceutical is also actively utilizing AI in drug development. The company's AI platform, 'HARP-pSAR,' has led to the identification of an obesity drug candidate, 'HM17321,' which is currently undergoing Phase 1 clinical trials in the United States.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.